БЕЗОПАСНОСТЬ ГИПОТЕНЗИВНЫХ СРЕДСТВ: ФОКУС НА ИНГИБИТОРЫ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА

Согласно Руководству по лечению артериальной гипертензии Европейского общества кардиологов и Европейского общества гипертонии, одним из основных классов лекарственных препаратов, рекомендованных к применению при артериальной гипертензии, являются ингибиторы ангиотензинпревращающего фермента. Результаты многочисленных исследований подтвердили, что эти препараты снижают риск общей смертности и летальности от сердечно-сосудистых заболеваний. Однако применение лекарственных препаратов данной группы ассоциируется с риском развития нежелательных реакций, основными из которых является сухой кашель, ортостатический коллапс, гиперкалиемия, ангионевротический отек. Обзор посвящен изучению профиля безопасности препаратов группы «ингибиторы ангиотензинпревращающего фермента», а также особенностей развития нежелательных реакций при их применении у разных категорий больных с целью возможного повышения приверженности пациентов к проводимой гипотензивной фармакотерапии и снижения риска развития осложнений со стороны сердечно-сосудистой системы.

артериальная гипертензия, ингибиторы ангиотензинпревращающего фермента, нежелательные реакции, кашель

1. Кобалава, Ж. Д. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 / Ж. Д. Кобалава, А. О. Конради, С. В. Недогода, Е. В. Шляхто // Российский кардиологический журнал. - 2020. - Т. 25, № 3. - С. 3786. doi:10.15829/1560-4071-2020-3-3786.

2. Ahuja, T. S. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors / T. S. Ahuja, D. Jr. Freeman, J. D. Mahnken, M. Agraharkar, M. Siddiqui, A. Memon // Am. J. Nephrol. - 2000. - Vol. 20, № 4. - P. 268-272. doi: 10.1159/000013599.

3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat) // JAMA. - 2002. - № 288. - P. 2981-2997.

4. Azzouz, B. Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature / B. Azzouz, A. Morel, L. Kanagaratnam, E. Herlem, T. Trenque // Drug Saf. - 2019. - Vol. 42, № 12. - P. 1507-1513. doi:10.1007/s40264-019-00865-8.

5. Baker-Goering, M. M. Relationship Between Adherence to Antihypertensive Medication Regimen and Out-of-Pocket Costs Among People Aged 35 to 64 With Employer-Sponsored Health Insurance / M. M. Baker-Goering, K.Roy, D. H. Howard // Prev. Chronic Dis. - 2019. - № 16. - P. 180381. doi: http://dx.doi.org/10.5888/pcd16.180381external icon.

6. Bangalore, S. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference / S. Bangalore, S. Kumar, F. H. Messerli // Am. J. Med. - 2010. - Vol. 123, № 11. - P. 1016-1030. doi:10.1016/j.amjmed.2010.06.014.

7. Brugts, J. J. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease / J. J. Brugts, H. Arima, W. Remme, M. Bertrand, R. Ferrari, K. Fox, J. DiNicolantonio, S. MacMahon, J. Chalmers, F. Zijlstra, K. Caliskan, M. L. Simoons, J. J. Mourad, E. Boersma, K. M. Akkerhuis // Int. J. Cardiol. - 2014. - Vol. 176, № 3. - P. 718-723. doi:10.1016/j.ijcard.2014.07.108.

8. Campo, P. Angioedema induced by angiotensin-converting enzyme inhibitors / P. Campo, T. D. Fernandez, G. Canto, C. Mayorga // Curr. Opin. Allergy Clin. Immunol. - 2013. - Vol. 13, № 4. - P. 337-344. doi:10.1097/ACI.0b013e328362b835.

9. Cheng, J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis / J. Cheng, W. Zhang, X. Zhang, F. Han, X. Li, X. He, Q. Li, J. Chen// JAMA Intern. Med. - 2014. - № 174. - P. 773-785.

10. Chow, C. K. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries / C. K. Chow, K. K. Teo, S. Rangarajan, S. Islam, R. Gupta, A. Avezum, A. Bahonar, J. Chifamba, G. Dagenais, R. Diaz, K. Kazmi, F. Lanas, L. Wei, P. Lopez-Jaramillo, L. Fanghong, N. H. Ismail, T. Puoane, A. Rosengren, A. Szuba, A. Temizhan, A. Wielgosz, R. Yusuf, A.Yusufali, M. McKee, L. Liu, P. Mony, S. Yusuf // JAMA. - 2013. - Vol. 310. - P. 959-968. doi:10.1001/jama.2013.184182.

11. Curb, J. D. Long-term Surveillance for Adverse Effects of Antihypertensive Drugs / J. D. Curb, N.O.Borhani, T. P. Blaszkowski, N. Zimbaldi, S. Fotiu, W. Williams // JAMA. - 1985. - Vol. 253, № 22. - P. 3263-3268. doi:10.1001/jama.1985.03350460063022.

12. Dahlof, B. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol / B. Dahlof, R. B. Devereux, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel // Lancet. - 2002. - № 359. - P. 995-1003.

13. Dicpinigaitis, P. V. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines / P. V. Dicpinigaitis // Chest. - 2006. - Vol. 129, № 1. - P. 169S-173S. doi: 10.1378/chest.129.1_suppl.169S.

14. Dixit, A. Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature / A. Dixit, G. Majumdar, P. Tewari // Ann. Card. Anaesth. - 2019. - Vol. 22, № 2. - P. 162-168. doi: 10.4103/aca.ACA_65_18.

15. Einhorn, L. M. The frequency of hyperkalemia and its significance in chronic kidney disease / L. M. Einhorn, M. Zhan, V. D. Hsu, L. D. Walker, M. F. Moen, S. L. Seliger, M. R. Weir, J. C. Fink // Arch. Intern. Med. - 2009. - № 169. - P. 1156-1162.

16. Falaschetti, E. Hypertension management in England: a serial cross-sectional study from 1994 to 2011 / E. Falaschetti, J. Mindell, C. Knott, N. Poulter // Lancet. - 2014. - № 383. - P. 1912-1919. doi: 10.1016/S0140-6736(14)60688-7.

17. Gebreyohannes, E. A. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital / E. A. Gebreyohannes, A. S. Bhagavathula, T. B. Abebe, Y. G. Tefera, T. M. Abegaz // Clin. Hypertens. - 2019. - № 25. - P. 1. doi:10.1186/s40885-018-0104-6.

18. Gupta, P. Risk Factors for Nonadherence to Antihypertensive Treatment / P. Gupta, P. Patel, B. Štrauch, F. Y. Lai, A. Akbarov, V. Marešová, C. M. J. White, O. Petrák, G. S. Gulsin, V. Patel, J. Rosa, R. Cole, T. Zelinka, R. Holaj, A. Kinnell, P. R. Smith, J. R. Thompso, I. Squire, J. Jr. Widimský, N. J. Saman, B. Williams, M.Tomaszewski // Hypertension. - 2017. - Vol. 69, № 6. - P. 1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729.

19. Hallberg, P. Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough / P. Hallberg, J. Nagy, M. Karawajczyk, L. Nordang, G. Islander, P. Norling, H. E. Johansson, M. Kämpe, S. Hugosson, Q. Y. Yue, M. Wadelius// Ann. Pharmacother. - 2017. - Vol. 51, № 4. - P. 293-300. doi: 10.1177/1060028016682251.

20. Izzo, J. L. Jr. Angiotensin-converting enzyme inhibitors / J. L. Jr. Izzo, M. R. Weir // J. Clin. Hypertens. (Greenwich). - 2011. - Vol. 13, № 9. - P. 667-675. doi: 10.1111/j.1751-7176.2011.00508.x.

21. Jamshed, F. Demographic and Clinical Characteristics of Patients Presenting With Angiotensin-converting Enzyme Inhibitors Induced Cough / F. Jamshed, H. Jaffry, H. Hanif, V. Kumar, U. Naz, M. Ahmed, S. Fareed // Cureus. - 2019. - Vol. 11, № 9. - P. e5624. doi:10.7759/cureus.5624.

22. Kaplan, R. P. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors / R. P. Kaplan, T. S. Potter, J. N. Fox // J. Am. Acad. Dermatol. - 1992. - Vol. 26, № 2 (2). - P. 364-366. doi: 10.1016/0190-9622(92)70057-m.

23. Krousel-Wood, M. A. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults / M. A. Krousel-Wood, P. Muntner, T. Islam, D. E. Morisky, L. S. Webber // Med Clin. North. Am. - 2009. - Vol. 93, № 3. - P. 753-769. doi:10.1016/j.mcna.2009.02.007.

24. Leon, S. J. New therapies for hyperkalemia / S. L. Leon, O. Harasemiw, N. Tangri // Curr. Opin. Nephrol. Hypertens. - 2019. - Vol. 28, № 3. - P. 238-244. doi: 10.1097/MNH.0000000000000500.

25. Lewis, E. J. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes / E. J. Lewis, L. G. Hunsicker, W. R. Clarke, T. Berl, M. A. Pohl, J. B. Lewis, E. Ritz, R. C. Atkins, R. Rohde, I. Raz // N. Engl. J. Med. - 2001 - Vol. 345, № 12 - P. 851-860. doi: 10.1056/NEJMoa011303.

26. Lewis, E. J. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group / E. J. Lewis, L. G. Hunsicker, R. P. Bain, R. D. Rohde // N. Engl. J. Med. - 1993. - Vol. 329, № 20. - P. 1456-1462. doi: 10.1056/NEJM199311113292004.

27. Liu, Y. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials / Y. Liu, X. Ma, J. Zheng, J. Jia, T. Yan // BMC Nephrol. - 2017. - Vol. 18, № 1. - P. 206. doi: 10.1186/s12882-017-0605-7.

28. Mahmoudpour, S. H. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors / S. H. Mahmoudpour, F. W. Asselbergs, C. E. de Keyser, P. C. Souverein, A. Hofman, B. H. Stricker, A. de Boer, A. H. Maitland-van der Zee // Int. J. Clin. Pharm. - 2015. - Vol. 37, № 6. - P. 1095-1103. doi: 10.1007/s11096-015-0159-3.

29. Materson, B. J. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril / B. J. Materson // Am. J. Cardiol. - 1992. - Vol. 69, № 10. - P. 46C-53C. doi: 10.1016/0002-9149(92)90281-3.

30. Messerli, F. H. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? / F. H. Messerli, S. Bangalore, C. Bavishi, S. F. Rimoldi// J. Am. Coll. Cardiol. - 2018. - Vol. 71, № 13. - P. 1474-1482. doi:10.1016/j.jacc.2018.01.058.

31. Morimoto, T. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors / T. Morimoto, T. K. Gandhi, J. M. Fiskio, A. C. Seger, J. W. So, E. F. Cook, T. Fukui, D. W. Bates // J. Eval. Clin. Pract. - 2004. - Vol. 10. - P. 499-509. doi:10.1111/j.1365-2753.2003.00484.x.

32. Natale, P. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease / P. Natale, S. C. Palmer, M. Ruospo, V. M. Saglimbene, G. F. Strippoli // Cochrane Database Syst. Rev. - 2020. - Vol. 6, № 6. - P. CD013165. doi: 10.1002/14651858.CD013165.pub2.

33. Ng, L. P. Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore / L. P. Ng, P. S. Goh // Singapore Med. J. - 2014. - Vol. 55, № 3. - P. 146-149. doi:10.11622/smedj.2014034.

34. Olsen, H. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway / H. Olsen, T. Klemetsrud, H. P. Stokke, S. Tretli, A. Westheim // Blood Pressure. - 1999. - Vol. 8, № 2. - P. 94-101. doi: 10.1080/080370599438266.

35. Onuigbo, M. A. Analytical Review of the Evidence for Renoprotection by Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease - A Call for Caution / M. A. Onuigbo // Nephron Clin. Pract. - 2009. - Vol. 113, № 2. - P. c63-c70. doi: 10.1159/000228536.

36. Onuigbo, M. A. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors / M. A. Onuigbo, N. T. Onuigbo // Ren. Fail. - 2008. - Vol. 30. - P. 73-80.

37. Palleria, C. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review / C. Palleria, L. Bennardo, S. Dastoli, L. F. Iannone, M. Silvestri, A. Manti, S. P. Nisticò, E. Russo, G. De Sarro // Dermatol. Ther. - 2019. - Vol. 32. № 1. - P. e12748. doi: 10.1111/dth.12748.

38. Palmer, B. F. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis / B. F. Palmer // Mayo Clin. Proc. - 2020. - Vol. 95, № 2. - P. 339-354. doi: 10.1016/j.mayocp.2019.05.019.

39. Peacock, E. Adherence to Antihypertensive Therapy / E. Peacock, M. Krousel-Wood // Med. Clin. North Am. - 2017. - Vol. 101, № 1. - P. 229-245. doi:10.1016/j.mcna.2016.08.005.

40. Raebel, M. A. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers / M. A. Raebel // Cardiovascular therapeutics. - 2012. - Vol. 30, № 3. - P. e156-e166.

41. Ramadan, F. H. Clinical factors associated with hyperkalemia in patients with congestive heart failure / F. H. Ramadan, N. Masoodi, A. A. El-Solh // J. Clin. Pharm. Ther. - 2005. - Vol. 30, № 3. - P. 233-239. doi: 10.1111/j.1365-2710.2005.00638.x.

42. Ravid, D. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure / D. Ravid, M. Lishner, R. Lang, M. Ravid // J. Clin. Pharmacol. - 1994. - Vol. 34, № 11. - P. 1116-1120. doi:10.1002/j.1552-4604.1994.tb01989.x.

43. Sangole, N. V. Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative study / N. V. Sangole, V. N. Dadkar // Indian J. Pharmacol. - 2010. - Vol. 42, № 1. - P. 27-31. doi: 10.4103/0253-7613.62408.

44. Santoro, A. Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS) / A. Santoro, M. Mandreoli // G. Ital. Nefrol. - 2018. - Vol. 35, № 3. - P. 2018-vol 3.

45. Schaefer, J. A. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy / J. A. Schaefer, M. A. Gales // Ann. Pharmacother. - 2016. - Vol. 50, № 6. - P. 502-510. doi: 10.1177/1060028016640794.

46. Shin, S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients / S. Shin, H. Song, S-K. Oh, K. E. Choi, H. Kim, S. Jang // Hypertens Res. - 2013. - Vol. 36, № 11. - P. 1000-1005. doi: 10.1038/hr.2013.85.

47. Singh, N. P. Angiotensin converting enzyme inhibitors and cough-a north Indian study / N. P. Singh, M. Uppal, S. Anuradha, A. Agarwal, S. N. Rizvi // J. Assoc. Physicians India. - 1998. - Vol. 46, № 5. - P. 448-451.

48. Sontheimer, R. D. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation / R. D. Sontheimer, C. L. Henderson, R. H. Grau // Arch. Dermatol. Res. - 2009. - Vol. 301, № 1. - P. 65-70. doi:10.1007/s00403-008-0890-x.

49. Strippoli, G. F. M. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease / G. F. M Strippoli, C. Bonifati, M. E. Craig, S. D. Navaneethan, J. C. Craig // Cochrane Database of Systematic Reviews. - 2006. - Vol. 4. - P. CD006257. doi: 10.1002/14651858.CD006257.

50. Svensson, P. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy / P. Svensson, U. De Faire, P. Sleight, S. Yusuf, J. Ostergren // Hypertension. - 2001. - Vol. 38. - P. E28-E32.

51. Taal, M. W. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists / M. W. Taal, B. M. Brenner // Perspectives in renal medicine. - 2000. - Vol. 57, № 5. - P. 1803-1817. doi: 10.1046/j.1523-1755.2000.00031.x.

52. The top 10 causes of death.WHO. - Режим доступа: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death, свободный. - Заглавие с экрана. - Яз. англ. - Дата обращения : 04.06.2020.

53. Tylicki, L. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions / L. Tylicki, S. Lizakowski, B. Rutkowski // J. Nephrol. - 2012. - Vol. 25, № 6. - P. 900-910. doi: 10.5301/jn.5000134.

54. Vukadinović, D. Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials / D. Vukadinović, A. N. Vukadinović, D. Lavall, U. Laufs, S. Wagenpfeil, M. Böhm // Clin. Pharmacol. Ther. - 2019. - Vol. 105, № 3. - P. 652-660. doi:10.1002/cpt.1018.

55. Zhang, F. Effects of RAAS Inhibitors in Patients with Kidney Disease / F. Zhang, H. Liu, D. Liu // Curr. Hypertens. Rep. - 2017. - Vol. 19, № 9. - P. 72. doi: 10.1007/s11906-017-0771-9. PMID: 28791529.

56. Williams, B. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension / B. Williams, G. Mancia, W. Spiering, E. AgabitiRosei, M. Azizi, M. Burnier, D. L. Clement, A. Coca, G. de Simone, A. Dominiczak, T. Kahan, F. Mahfoud, J. Redon, L. Ruilope, A. Zanchetti, M. Kerins, S. E. Kjeldsen, R. Kreutz, S. Laurent, G. Y. H. Lin, R. McManus, K. Narkiewicz, F. Ruschitzka, R. E. Schmieder, E. Shlyakhto, C. Tsioufis, V. Aboyans, I. Desormais // J. Hypertens. -2018. - Vol. 3, № 10. - P. 1953-2041. doi: 10.1097/HJH.0000000000001940.